Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Mylan IRE Healthcare Limited, Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
Klacid 250 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. A yellow, ovaloid, film-coated tablet. |
Each tablet contains 250 mg of Clarithromycin.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Clarithromycin |
Clarithromycin is a semi-synthetic derivative of erythromycin A. It exerts its antibacterial action by selectively binding to the 50s ribosomal sub-unit of susceptible bacteria preventing translocation of activated amino acids. It inhibits the intracellular protein synthesis of susceptible bacteria. |
| List of Excipients |
|---|
|
Tablet core: Croscarmellose sodium Tablet coat: Hypromellose, |
2, 14, 56 tablets in PVC/PVdC Al blister pack. The blisters are packaged in a carton with a pack insert. Not all pack sizes may be marketed.
Mylan IRE Healthcare Limited, Unit 35/36, Grange Parade, Baldoyle Industrial Estate, Dublin 13, Ireland
PA2010/004/001
Date of first authorisation: 20th November 1989
Date of last renewal: 20th November 2009
| Drug | Countries | |
|---|---|---|
| KLACID | Austria, Australia, Germany, Estonia, Spain, Finland, Hong Kong, Ireland, Israel, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
